胃癌新辅助治疗进展和展望

Neoadjuvant therapy in gastric cancer: Current status and future perspectives

胃癌在我国发病率较高,预后较差.多数患者确诊时已处于局部进展期,单纯手术治疗局部复发率高,生存状况较差,因此新辅助治疗受到关注.目前相关临床研究显示新辅助治疗使进展期患者获得临床受益,而有关新辅助治疗的最佳方式以及新辅助放化疗和新辅化疗的疗效比较仍需要更多前瞻性临床研究数据.

Gastric cancer （GC） remains one of the most common tumors in China. Most patients with GC in China are already in a locally advanced stage at the time of diagnosis. Neoadjuvant therapy has attracted increasing attention. Clinical literature and meta-analyses show that neoadjuvant therapy results in a significant survival benefit for resectable locally advanced GC,and preoperative chemoradiotherapy also should be a standard treatment for advanced GC vs surgery alone. The optimal regimens of neoadjuvant therapy and comparisons between preoperative chemotherapy and chemoradiotherapy still need to be studied further.